SCM
ELVN icon

Sterling Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Sterling Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.61K Sell
150
-106
-41% -$4.5K ﹤0.01% 2377
2026
Q1 		$10K Sell
256
-23
-8% -$637 ﹤0.01% 2369
2025
Q4 		$4.3K Buy
279
+177
+174% +$3.53K ﹤0.01% 2936
2025
Q3 		$2.09K Buy
102
+21
+26% +$423 ﹤0.01% 2970
2025
Q2 		$1.63K Buy
81
+14
+21% +$265 ﹤0.01% 2972
2025
Q1 		$1.32K Sell
67
-28
-29% -$603 ﹤0.01% 2722
2024
Q4 		$2.14K Buy
95
+55
+138% +$1.43K ﹤0.01% 2768
2024
Q3 		$1.02K Buy
+40
New +$926 ﹤0.01% 2518

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Sterling Capital Management's ELVN Position: Q2 2026 in Review

Sterling Capital Management reduced its Enliven Therapeutics (ELVN) stake by 41% in Q2 2026, selling an estimated $4.5K and leaving 150 shares worth $7.61K. The position accounts for ﹤0.01% of the portfolio, ranked #2377.

Sterling Capital Management first reported a position in ELVN in Q3 2024 and has held it in 8 quarters since. The position peaked at $10K in Q1 2026. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Sterling Capital Management held 150 shares of Enliven Therapeutics worth $7.61K as of Q2 2026.
  • Sterling Capital Management sold 106 Enliven Therapeutics shares in Q2 2026, an estimated $4.5K.
  • Enliven Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2377 holding.
  • Sterling Capital Management first reported a position in Enliven Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Enliven Therapeutics position peaked at $10K in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.